A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs GSK 2256098 (Primary) ; Trametinib (Primary)
- Indications Mesothelioma; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 08 Nov 2016 Status changed from recruiting to completed.
- 09 Jun 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016.